MBOAT7

Across TCGA pan-cancer cohorts, MBOAT7 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MBOAT7 data layer compared with 19 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MBOAT7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MBOAT7 expression acts as an unfavorable survival marker.

LUSC, PAAD, and SARC are the cancer types where MBOAT7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.253	0.721	<.001	28	view →
PAAD	OS	Median	All	0.100	0.614	<.001	24	view →
SARC	OS	Median	All	0.108	0.827	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
BRCA	DFS	Median	All	0.708	0.949	<.001	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.198	0.613	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MBOAT7–LUSC (DFS)

Open the LUSC breakdown →